|
Liquidia Corporation (NASDAQ: LQDA) |
|
Liquidia Corporation
LQDA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Liquidia's sales fell
by -35.62 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2130
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Liquidia net loss increased from $-27 millions, to $-38 millions in IV. Quarter 2024,
• More on LQDA's Growth
|
|
Liquidia realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 11.95 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 79.25.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on LQDA's Valuation
|
|
|
|
|
Liquidia realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 11.95 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 79.25.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
Liquidia Price to Book Ratio is at 14.35 lower than Industry Avg. of 79.76. and higher than S&P 500 Avg. of 0.01
• More on LQDA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com